Better therapeutics through microarrays - PubMed (original) (raw)

Review

. 2002 Dec:32 Suppl:547-51.

doi: 10.1038/ng1042.

Affiliations

• PMID: 12454652
• DOI: 10.1038/ng1042

Review

Better therapeutics through microarrays

David L Gerhold et al. Nat Genet. 2002 Dec.

Abstract

DNA microarrays are an integral part of the process for therapeutic discovery, optimization and clinical validation. At an early stage, investigators use arrays to prioritize a few genes as potential therapeutic targets on the basis of various criteria. Subsequently, gene expression analysis assists in drug discovery and toxicology by eliminating poor compounds and optimizing the selection of promising leads. Integral to this process is the use of sophisticated statistics, mathematics and bioinformatics to define statistically valid observations and to deduce complex patterns of phenotypes and biological pathways. In short, microarrays are redefining the drug discovery process by providing greater knowledge at each step and by illuminating the complex workings of biological systems.

PubMed Disclaimer

Similar articles

• DNA microarrays in drug discovery and development.
  Debouck C, Goodfellow PN. Debouck C, et al. Nat Genet. 1999 Jan;21(1 Suppl):48-50. doi: 10.1038/4475. Nat Genet. 1999. PMID: 9915501 Review.
• Gene expression profiling in drug discovery and development.
  Stratowa C, Wilgenbus KK. Stratowa C, et al. Curr Opin Mol Ther. 1999 Dec;1(6):671-9. Curr Opin Mol Ther. 1999. PMID: 19629863 Review.
• DNA microarrays: vital statistics.
  Tilstone C. Tilstone C. Nature. 2003 Aug 7;424(6949):610-2. doi: 10.1038/424610a. Nature. 2003. PMID: 12904757 No abstract available.
• DNA microarrays and pharmacogenomics.
  Meloni R, Khalfallah O, Biguet NF. Meloni R, et al. Pharmacol Res. 2004 Apr;49(4):303-8. doi: 10.1016/j.phrs.2003.06.001. Pharmacol Res. 2004. PMID: 15202510 Review.
• Microarrays: spotlight on gene function and pharmacogenomics.
  Nees M, Woodworth CD. Nees M, et al. Curr Cancer Drug Targets. 2001 Aug;1(2):155-75. doi: 10.2174/1568009013334197. Curr Cancer Drug Targets. 2001. PMID: 12188888 Review.

Cited by

• Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis.
  Lu Z, Gao Y. Lu Z, et al. Ann Med. 2021 Dec;53(1):1377-1389. doi: 10.1080/07853890.2021.1966087. Ann Med. 2021. PMID: 34409913 Free PMC article.
• Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders.
  Menke A. Menke A. Pharmgenomics Pers Med. 2018 Nov 19;11:211-222. doi: 10.2147/PGPM.S146110. eCollection 2018. Pharmgenomics Pers Med. 2018. PMID: 30510440 Free PMC article. Review.
• A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A).
  Golla U, Swagatika S, Chauhan S, Tomar RS. Golla U, et al. Oncotarget. 2017 Sep 30;8(58):98426-98454. doi: 10.18632/oncotarget.21416. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228701 Free PMC article.
• Combined Transcriptomics and Chemical-Genetics Reveal Molecular Mode of Action of Valproic acid, an Anticancer Molecule using Budding Yeast Model.
  Golla U, Joseph D, Tomar RS. Golla U, et al. Sci Rep. 2016 Oct 13;6:35322. doi: 10.1038/srep35322. Sci Rep. 2016. PMID: 27734932 Free PMC article.
• Improvement of experimental testing and network training conditions with genome-wide microarrays for more accurate predictions of drug gene targets.
  Christadore LM, Pham L, Kolaczyk ED, Schaus SE. Christadore LM, et al. BMC Syst Biol. 2014 Jan 20;8:7. doi: 10.1186/1752-0509-8-7. BMC Syst Biol. 2014. PMID: 24444313 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database